<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02987855</url>
  </required_header>
  <id_info>
    <org_study_id>RSD-CRPS</org_study_id>
    <nct_id>NCT02987855</nct_id>
  </id_info>
  <brief_title>Adipose Stem/Stromal Cells in RSD, CRPS, Fibromyalgia</brief_title>
  <acronym>ADcSVF-CRPS</acronym>
  <official_title>Use of Autologous Adult Adipose-Derived Stem/Stromal Cells in Reflex Sympathetic Dystrophy (RSD), Complex Regional Pain Syndrome (CRPS), and Fibromyalgia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Healeon Medical Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Healeon Medical Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Reflex Sympathetic Dystrophy (RSD), Complex Regional Pain Syndrome (CRPS), Causalgia, and&#xD;
      Fibromyalgia represent progressive systemic pain conditions which often worsen over time.&#xD;
      They appear to be dysregulation of the central nervous system (CNS) and the autonomic system&#xD;
      (sympathetic/parasympathetic) which cause extensive functional losses, impairment, and&#xD;
      disabilities. They are often associated with injury sites (including surgical) which produce&#xD;
      constant, often disabling pain and motor-sensory losses.&#xD;
&#xD;
      Treatments are often ineffective and include medications (often high dose opiates), Physical&#xD;
      Therapy (PT), and surgical interventions (sympathectomy, ablation) or insertion stimulators&#xD;
      of the CNS.&#xD;
&#xD;
      Study is an interventional study to document the safety and efficacy of use of&#xD;
      adipose-derived cellular stromal vascular fraction (AD-cSVF) in chronic pain and dysfunction&#xD;
      disease groups.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Reflex Sympathetic Dystrophy (RSD), Complex Regional Pain Syndrome (CRPS), Causalgia, and&#xD;
      Fibromyalgia represent progressive systemic pain conditions which often worsen over time.&#xD;
      They appear to be dysregulation of the central nervous system (CNS) and the autonomic system&#xD;
      (sympathetic/parasympathetic) which cause extensive functional losses, impairment, and&#xD;
      disabilities. They are often associated with injury sites (including surgical) which produce&#xD;
      constant, often disabling pain and motor-sensory losses.&#xD;
&#xD;
      Treatments are often ineffective and include medications (often high dose opiates), physical&#xD;
      therapy (PT(, and surgical interventions (sympathectomy, ablation) or insertion stimulators&#xD;
      of the CNS.&#xD;
&#xD;
      Clinical Features include neurogenic inflammation, nociceptive sensitization, vasomotor&#xD;
      dysfunction and maladaptive neuroplasticity. As these often seem related to specific injury&#xD;
      sites (trauma, surgical, etc.) which are followed with severe pain sensations such as&#xD;
      stabbing, burning, throbbing, and local muscular spasms or hemiparesis. In addition, there&#xD;
      are many reports of visual change, dropping attacks (sudden falling), joint soreness, and&#xD;
      other systemic symptoms associated with potentially any organ in the body.&#xD;
&#xD;
      Diagnosis typically recognizes 3 distinct &quot;types&quot; which do not appear to be sequential in&#xD;
      nature. Type 1 characterization is severe, burning sensory change near an injury site,&#xD;
      musculoskeletal and joint stiffness. Type 2 demonstrates very high pain levels, swelling,&#xD;
      muscular atrophy, joint degeneration, depression, and other concomitant dysfunctions. Type 3&#xD;
      features irreversible changes to skin/bone, and extreme loss of function of muscle (atrophic&#xD;
      primarily) and tendons. A significant percentage (13-70 ) are felt to be at risk if&#xD;
      neurological injuries, hemiplegia, enhanced vasomotor issues due to enhanced sympathetic&#xD;
      actions and neurotransmission issues.&#xD;
&#xD;
      This study includes microcannula harvesting of subdermal adipose tissues, incubation,&#xD;
      digestion and isolation of AD-cSVF. This stromal cellular pellet (without actual&#xD;
      extracellular matrix or stromal elements) is then suspended in 500 cc sterile Normal Saline&#xD;
      (NS) and deployed via peripheral intravenous route. Evaluations of safety issues are measured&#xD;
      at intervals (both severe and non-severe categories) and by repeated pulmonary function&#xD;
      studies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Withdrawn [COVID restrictions prevent patient enrollment or treatment. Clinical Trial facility&#xD;
    is being closed due to viral limitations and loss of staff to perform]&#xD;
  </why_stopped>
  <start_date type="Actual">December 15, 2018</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse and Severe Adverse Reaction Report</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluate any Adverse or Severe Adverse Reactions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline Pain Levels</measure>
    <time_frame>1 month, 6 month, 1 year</time_frame>
    <description>Pain Scale Questionnaire 1-10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life from Baseline</measure>
    <time_frame>6 months, 12 months</time_frame>
    <description>Quality of Life Questionnaire (QoL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline of Lifestyle</measure>
    <time_frame>6 months, 12 months</time_frame>
    <description>Fibromyalgia Impact Questionnaire (FIQR)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>RSD (Reflex Sympathetic Dystrophy)</condition>
  <condition>CRPS - Complex Regional Pain Syndrome Type I</condition>
  <condition>Fibromyalgia</condition>
  <arm_group>
    <arm_group_label>Lipoaspiration Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acquisition of Adipose-Derived tissue Stromal Vascular Fraction (AD-tSVF) via closed syringe lipoaspiration harvest of subdermal fat</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AD-cSVF Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ADcSVF Isolation of cellular stem/stromal cells from subdermal adipose-derived cellular stromal vascular fraction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline IV Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Normal Saline IV with AD-cSVF cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Lipoaspiration</intervention_name>
    <description>Closed syringe harvesting subdermal fat</description>
    <arm_group_label>Lipoaspiration Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ADcSVF isolation</intervention_name>
    <description>Isolation of AD-cSVF from lipoaspirate via enzymatic digestion</description>
    <arm_group_label>AD-cSVF Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Normal Saline IV</intervention_name>
    <description>Normal Saline IV containing autologous AD-cSVF</description>
    <arm_group_label>Normal Saline IV Arm 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with confirmed diagnosis of RSD, CRPS, and severe Fibromyalgia&#xD;
&#xD;
          -  Ability to provide Informed Consent (or as parent or legal guardian)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with severe comorbidities which, in opinion of PI or provider associates.&#xD;
             would be unsafe or not advised to be able to comply with study or follow up&#xD;
             requirements&#xD;
&#xD;
          -  Patients with documented Opiate abuse&#xD;
&#xD;
          -  Patient taking corticosteroid therapy, immune suppression, or chemotherapeutic regimen&#xD;
             within 6 months of entry&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Glenn C Terry, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Global Alliance for Regenerative Medicine (GARM)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Regenevita LLC</name>
      <address>
        <city>Stevensville</city>
        <state>Montana</state>
        <zip>59870</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GARM</name>
      <address>
        <city>Roatan</city>
        <state>Hn</state>
        <country>Honduras</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Honduras</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Schwartzman RJ, Erwin KL, Alexander GM. The natural history of complex regional pain syndrome. Clin J Pain. 2009 May;25(4):273-80. doi: 10.1097/AJP.0b013e31818ecea5.</citation>
    <PMID>19590474</PMID>
  </reference>
  <reference>
    <citation>Marinus J, Moseley GL, Birklein F, Baron R, Maihofner C, Kingery WS, van Hilten JJ. Clinical features and pathophysiology of complex regional pain syndrome. Lancet Neurol. 2011 Jul;10(7):637-48. doi: 10.1016/S1474-4422(11)70106-5.</citation>
    <PMID>21683929</PMID>
  </reference>
  <reference>
    <citation>Veldman PH, Reynen HM, Arntz IE, Goris RJ. Signs and symptoms of reflex sympathetic dystrophy: prospective study of 829 patients. Lancet. 1993 Oct 23;342(8878):1012-6. doi: 10.1016/0140-6736(93)92877-v.</citation>
    <PMID>8105263</PMID>
  </reference>
  <reference>
    <citation>Maihofner C, Forster C, Birklein F, Neundorfer B, Handwerker HO. Brain processing during mechanical hyperalgesia in complex regional pain syndrome: a functional MRI study. Pain. 2005 Mar;114(1-2):93-103. doi: 10.1016/j.pain.2004.12.001. Epub 2005 Jan 26.</citation>
    <PMID>15733635</PMID>
  </reference>
  <reference>
    <citation>Watkins LR, Maier SF. Immune regulation of central nervous system functions: from sickness responses to pathological pain. J Intern Med. 2005 Feb;257(2):139-55. doi: 10.1111/j.1365-2796.2004.01443.x.</citation>
    <PMID>15656873</PMID>
  </reference>
  <reference>
    <citation>Birklein F. Complex regional pain syndrome. J Neurol. 2005 Feb;252(2):131-8. doi: 10.1007/s00415-005-0737-8.</citation>
    <PMID>15729516</PMID>
  </reference>
  <reference>
    <citation>Lee BH, Scharff L, Sethna NF, McCarthy CF, Scott-Sutherland J, Shea AM, Sullivan P, Meier P, Zurakowski D, Masek BJ, Berde CB. Physical therapy and cognitive-behavioral treatment for complex regional pain syndromes. J Pediatr. 2002 Jul;141(1):135-40. doi: 10.1067/mpd.2002.124380.</citation>
    <PMID>12091866</PMID>
  </reference>
  <reference>
    <citation>van de Meent H, Oerlemans M, Bruggeman A, Klomp F, van Dongen R, Oostendorp R, Frolke JP. Safety of &quot;pain exposure&quot; physical therapy in patients with complex regional pain syndrome type 1. Pain. 2011 Jun;152(6):1431-1438. doi: 10.1016/j.pain.2011.02.032. Epub 2011 Apr 6.</citation>
    <PMID>21474244</PMID>
  </reference>
  <reference>
    <citation>Swart CM, Stins JF, Beek PJ. Cortical changes in complex regional pain syndrome (CRPS). Eur J Pain. 2009 Oct;13(9):902-7. doi: 10.1016/j.ejpain.2008.11.010. Epub 2008 Dec 19.</citation>
    <PMID>19101181</PMID>
  </reference>
  <reference>
    <citation>Chopra P, Cooper MS. Treatment of Complex Regional Pain Syndrome (CRPS) using low dose naltrexone (LDN). J Neuroimmune Pharmacol. 2013 Jun;8(3):470-6. doi: 10.1007/s11481-013-9451-y. Epub 2013 Apr 2.</citation>
    <PMID>23546884</PMID>
  </reference>
  <reference>
    <citation>Azari P, Lindsay DR, Briones D, Clarke C, Buchheit T, Pyati S. Efficacy and safety of ketamine in patients with complex regional pain syndrome: a systematic review. CNS Drugs. 2012 Mar 1;26(3):215-28. doi: 10.2165/11595200-000000000-00000.</citation>
    <PMID>22136149</PMID>
  </reference>
  <reference>
    <citation>Opal SM, Wiest PM, Olds GR. Traveler's diarrhea: methods of prevention and treatment. R I Med J (1976). 1990 May;73(5):199-204.</citation>
    <PMID>2343234</PMID>
  </reference>
  <reference>
    <citation>Varenna M, Adami S, Rossini M, Gatti D, Idolazzi L, Zucchi F, Malavolta N, Sinigaglia L. Treatment of complex regional pain syndrome type I with neridronate: a randomized, double-blind, placebo-controlled study. Rheumatology (Oxford). 2013 Mar;52(3):534-42. doi: 10.1093/rheumatology/kes312. Epub 2012 Nov 30.</citation>
    <PMID>23204550</PMID>
  </reference>
  <reference>
    <citation>Gainer MJ. Hypnotherapy for reflex sympathetic dystrophy. Am J Clin Hypn. 1992 Apr;34(4):227-32. doi: 10.1080/00029157.1992.10402852.</citation>
    <PMID>1349789</PMID>
  </reference>
  <reference>
    <citation>Hamdi TN. The Copeland intraocular lens: five to ten years later. Ophthalmology. 1979 Jun;86(6):984-96. doi: 10.1016/s0161-6420(79)35409-4.</citation>
    <PMID>534104</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 5, 2016</study_first_submitted>
  <study_first_submitted_qc>December 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2016</study_first_posted>
  <last_update_submitted>February 14, 2021</last_update_submitted>
  <last_update_submitted_qc>February 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Healeon Medical Inc</investigator_affiliation>
    <investigator_full_name>Robert W. Alexander, MD, FICS</investigator_full_name>
    <investigator_title>Principal Investigator, Science</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
    <mesh_term>Complex Regional Pain Syndromes</mesh_term>
    <mesh_term>Reflex Sympathetic Dystrophy</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02987855
org study id: RSD-CRPS
nct id: NCT02987855
lead sponsor: 
has dmc: Yes
is fda regulated drug: No
is fda regulated device: No
Reflex Sympathetic Dystrophy (RSD), Complex Regional Pain Syndrome (CRPS), Causalgia, and
      Fibromyalgia represent progressive systemic pain conditions which often worsen over time.
      They appear to be dysregulation of the central nervous system (CNS) and the autonomic system
      (sympathetic/parasympathetic) which cause extensive functional losses, impairment, and
      disabilities. They are often associated with injury sites (including surgical) which produce
      constant, often disabling pain and motor-sensory losses.

      Treatments are often ineffective and include medications (often high dose opiates), Physical
      Therapy (PT), and surgical interventions (sympathectomy, ablation) or insertion stimulators
      of the CNS.

      Study is an interventional study to document the safety and efficacy of use of
      adipose-derived cellular stromal vascular fraction (AD-cSVF) in chronic pain and dysfunction
      disease groups.
Reflex Sympathetic Dystrophy (RSD), Complex Regional Pain Syndrome (CRPS), Causalgia, and
      Fibromyalgia represent progressive systemic pain conditions which often worsen over time.
      They appear to be dysregulation of the central nervous system (CNS) and the autonomic system
      (sympathetic/parasympathetic) which cause extensive functional losses, impairment, and
      disabilities. They are often associated with injury sites (including surgical) which produce
      constant, often disabling pain and motor-sensory losses.

      Treatments are often ineffective and include medications (often high dose opiates), physical
      therapy (PT(, and surgical interventions (sympathectomy, ablation) or insertion stimulators
      of the CNS.

      Clinical Features include neurogenic inflammation, nociceptive sensitization, vasomotor
      dysfunction and maladaptive neuroplasticity. As these often seem related to specific injury
      sites (trauma, surgical, etc.) which are followed with severe pain sensations such as
      stabbing, burning, throbbing, and local muscular spasms or hemiparesis. In addition, there
      are many reports of visual change, dropping attacks (sudden falling), joint soreness, and
      other systemic symptoms associated with potentially any organ in the body.

      Diagnosis typically recognizes 3 distinct "types" which do not appear to be sequential in
      nature. Type 1 characterization is severe, burning sensory change near an injury site,
      musculoskeletal and joint stiffness. Type 2 demonstrates very high pain levels, swelling,
      muscular atrophy, joint degeneration, depression, and other concomitant dysfunctions. Type 3
      features irreversible changes to skin/bone, and extreme loss of function of muscle (atrophic
      primarily) and tendons. A significant percentage (13-70 ) are felt to be at risk if
      neurological injuries, hemiplegia, enhanced vasomotor issues due to enhanced sympathetic
      actions and neurotransmission issues.

      This study includes microcannula harvesting of subdermal adipose tissues, incubation,
      digestion and isolation of AD-cSVF. This stromal cellular pellet (without actual
      extracellular matrix or stromal elements) is then suspended in 500 cc sterile Normal Saline
      (NS) and deployed via peripheral intravenous route. Evaluations of safety issues are measured
      at intervals (both severe and non-severe categories) and by repeated pulmonary function
      studies.
allocation: Non-Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: Single (Participant)
measure: Adverse and Severe Adverse Reaction Report
time frame: 12 months
description: Evaluate any Adverse or Severe Adverse Reactions
measure: Change from Baseline Pain Levels
time frame: 1 month, 6 month, 1 year
description: Pain Scale Questionnaire 1-10
measure: Change in Quality of Life from Baseline
time frame: 6 months, 12 months
description: Quality of Life Questionnaire (QoL)
measure: Change from Baseline of Lifestyle
time frame: 6 months, 12 months
description: Fibromyalgia Impact Questionnaire (FIQR)
arm group label: Lipoaspiration Arm 1
arm group type: Experimental
description: Acquisition of Adipose-Derived tissue Stromal Vascular Fraction (AD-tSVF) via closed syringe lipoaspiration harvest of subdermal fat
arm group label: AD-cSVF Arm 2
arm group type: Experimental
description: ADcSVF Isolation of cellular stem/stromal cells from subdermal adipose-derived cellular stromal vascular fraction
arm group label: Normal Saline IV Arm 3
arm group type: Experimental
description: Normal Saline IV with AD-cSVF cells
intervention type: Procedure
intervention name: Lipoaspiration
description: Closed syringe harvesting subdermal fat
arm group label: Lipoaspiration Arm 1
intervention type: Procedure
intervention name: ADcSVF isolation
description: Isolation of AD-cSVF from lipoaspirate via enzymatic digestion
arm group label: AD-cSVF Arm 2
intervention type: Procedure
intervention name: Normal Saline IV
description: Normal Saline IV containing autologous AD-cSVF
arm group label: Normal Saline IV Arm 3
criteria: 
gender: All
minimum age: 16 Years
maximum age: N/A
healthy volunteers: No
last name: Glenn C Terry, MD
role: Principal Investigator
affiliation: Global Alliance for Regenerative Medicine (GARM)
facility: 
facility: 
country: Honduras
country: United States
citation: Schwartzman RJ, Erwin KL, Alexander GM. The natural history of complex regional pain syndrome. Clin J Pain. 2009 May;25(4):273-80. doi: 10.1097/AJP.0b013e31818ecea5.
PMID: 19590474
citation: Marinus J, Moseley GL, Birklein F, Baron R, Maihofner C, Kingery WS, van Hilten JJ. Clinical features and pathophysiology of complex regional pain syndrome. Lancet Neurol. 2011 Jul;10(7):637-48. doi: 10.1016/S1474-4422(11)70106-5.
PMID: 21683929
citation: Veldman PH, Reynen HM, Arntz IE, Goris RJ. Signs and symptoms of reflex sympathetic dystrophy: prospective study of 829 patients. Lancet. 1993 Oct 23;342(8878):1012-6. doi: 10.1016/0140-6736(93)92877-v.
PMID: 8105263
citation: Maihofner C, Forster C, Birklein F, Neundorfer B, Handwerker HO. Brain processing during mechanical hyperalgesia in complex regional pain syndrome: a functional MRI study. Pain. 2005 Mar;114(1-2):93-103. doi: 10.1016/j.pain.2004.12.001. Epub 2005 Jan 26.
PMID: 15733635
citation: Watkins LR, Maier SF. Immune regulation of central nervous system functions: from sickness responses to pathological pain. J Intern Med. 2005 Feb;257(2):139-55. doi: 10.1111/j.1365-2796.2004.01443.x.
PMID: 15656873
citation: Birklein F. Complex regional pain syndrome. J Neurol. 2005 Feb;252(2):131-8. doi: 10.1007/s00415-005-0737-8.
PMID: 15729516
citation: Lee BH, Scharff L, Sethna NF, McCarthy CF, Scott-Sutherland J, Shea AM, Sullivan P, Meier P, Zurakowski D, Masek BJ, Berde CB. Physical therapy and cognitive-behavioral treatment for complex regional pain syndromes. J Pediatr. 2002 Jul;141(1):135-40. doi: 10.1067/mpd.2002.124380.
PMID: 12091866
citation: van de Meent H, Oerlemans M, Bruggeman A, Klomp F, van Dongen R, Oostendorp R, Frolke JP. Safety of "pain exposure" physical therapy in patients with complex regional pain syndrome type 1. Pain. 2011 Jun;152(6):1431-1438. doi: 10.1016/j.pain.2011.02.032. Epub 2011 Apr 6.
PMID: 21474244
citation: Swart CM, Stins JF, Beek PJ. Cortical changes in complex regional pain syndrome (CRPS). Eur J Pain. 2009 Oct;13(9):902-7. doi: 10.1016/j.ejpain.2008.11.010. Epub 2008 Dec 19.
PMID: 19101181
citation: Chopra P, Cooper MS. Treatment of Complex Regional Pain Syndrome (CRPS) using low dose naltrexone (LDN). J Neuroimmune Pharmacol. 2013 Jun;8(3):470-6. doi: 10.1007/s11481-013-9451-y. Epub 2013 Apr 2.
PMID: 23546884
citation: Azari P, Lindsay DR, Briones D, Clarke C, Buchheit T, Pyati S. Efficacy and safety of ketamine in patients with complex regional pain syndrome: a systematic review. CNS Drugs. 2012 Mar 1;26(3):215-28. doi: 10.2165/11595200-000000000-00000.
PMID: 22136149
citation: Opal SM, Wiest PM, Olds GR. Traveler's diarrhea: methods of prevention and treatment. R I Med J (1976). 1990 May;73(5):199-204.
PMID: 2343234
citation: Varenna M, Adami S, Rossini M, Gatti D, Idolazzi L, Zucchi F, Malavolta N, Sinigaglia L. Treatment of complex regional pain syndrome type I with neridronate: a randomized, double-blind, placebo-controlled study. Rheumatology (Oxford). 2013 Mar;52(3):534-42. doi: 10.1093/rheumatology/kes312. Epub 2012 Nov 30.
PMID: 23204550
citation: Gainer MJ. Hypnotherapy for reflex sympathetic dystrophy. Am J Clin Hypn. 1992 Apr;34(4):227-32. doi: 10.1080/00029157.1992.10402852.
PMID: 1349789
citation: Hamdi TN. The Copeland intraocular lens: five to ten years later. Ophthalmology. 1979 Jun;86(6):984-96. doi: 10.1016/s0161-6420(79)35409-4.
PMID: 534104
responsible party type: Principal Investigator
investigator affiliation: Healeon Medical Inc
investigator full name: Robert W. Alexander, MD, FICS
investigator title: Principal Investigator, Science
mesh term: Fibromyalgia
mesh term: Myofascial Pain Syndromes
mesh term: Complex Regional Pain Syndromes
mesh term: Reflex Sympathetic Dystrophy
mesh term: Syndrome
sharing ipd: No